干扰素联合恩替卡韦对慢性乙型病毒肝炎初治患者的疗效观察

王周勋

（陕西省宝鸡市岐山县医院感染科，陕西 宝鸡，722400）

浏览次数：120次 下载次数：427次

摘要：

目的 探讨干扰素与恩替卡韦联合治疗慢性乙型病毒肝炎初治患者的临床效果。方法 选取2014年6月至2016年1月我院慢性乙型病毒肝炎初次治疗患者76例为研究对象，经随机数字表法分为观察组与对照组，各38例。对照组给予干扰素治疗，观察组在对照组基础上加用恩替卡韦治疗，观察两组患者病毒学、血清学指标，肝功能指标及不良反应发生情况。结果 治疗8周后，两组HBV DNA转阴率、HBeAg转阴率及HBeAg血清转换率比较，差异无统计学意义（P>0.05）；治疗24周后，观 察组患者上述指标显著高于对照组，差异有统计学意义（P<0.05）；治疗48周后，观察组患者上述指标显著高于对照组，差异有统计学意义（P<0.05）。治疗前两组患者血清AST、ALT水平比较，无显著差异（P>0.05）；治疗48周后，观察组患者血清 AST、ALT水平明显低于对照组，差异有统计学意义（P<0.05）。两组不良反应发生率比较，差异无统计学意义（P> 0.05）。结论慢性乙型病毒肝炎初治患者接受干扰素联合恩替卡韦治疗效果确切，可显著改善肝功能，且安全性高，值得推广。

关键词：乙型病毒性肝炎；恩替卡韦；干扰素；肝功能

中图分类号：R512.62文献标志码：A文章编号：2096-1413(2017)15-0037-03

Clinical observation of interferon combined with entecavir in the treatment of patients with chronic hepatitis B
WANG Zhou-xun
(Department of Infectious Diseases, Qishan County Hospital, Baoji 722400, China)

ABSTRACT: Objective To investigate the clinical effect of interferon combined with entecavir in the treatment of patients with chronic hepatitis B. Methods From June 2014 to January 2016, 76 cases of patients with chronic hepatitis B in our hospital treated first time were selected as the research objects and randomly divided into observation group and control group, with 38 cases in each group. The control group was given interferon treatment, and the observation group added entecavir based on the control group. The virological and serological indexes, liver function index and the incidence of adverse reactions were observed in the two groups. Results After 8 weeks of treatment, the differences of HBV DNA negative rate, HBeAg negative rate and HBeAg serum conversion rate in the two groups had no statistical significance (P>0.05); after 24 weeks of treatment, the above indexes in the observation group were significantly higher than those in the control group (P<0.05); after 48 weeks of treatment, the above indexes in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference of serum AST and ALT levels between the two groups before treatment (P>0.05); after 48 weeks of treatment, the serum AST and ALT levels in the two groups decreased (P<0.05), and the observation group were significantly lower than those in the control group, the differences were statistically significant (P<0.05). There was no significant difference of incidence of adverse reactions between the two groups (P>0.05).Conclusion Interferon combined with entecavir in the treatment of patients with chronic hepatitis B has exact treatment effect, which can significantly improve liver function with high safety, it is worth promoting.
KEYWORDS：hepatitis B virus; entecavir; interferon; liver function

参考文献：
[1] 李晶.琢-干扰素联合恩替卡韦治疗慢性乙型肝炎早期疗效[J].肝脏,2012,17(10):714-716.
[2] 慢性乙型肝炎抗病毒治疗专家共识专家委员会.慢性乙型肝炎抗病毒治疗专家共识[J].临床肝胆病杂志:电子版,2010,2(1):125-130.
[3] 中华医学会肝病学分会.慢性乙型肝炎防治指南(2015 年版)[J].实用肝脏病杂志:电子版,2016,19(3):389-400.
[4] 周一鸣,曹建彪,郭汉斌,等.恩替卡韦联合干扰素治疗e抗原阳性慢性乙型肝炎疗效观察[J].临床内科杂志,2013,30(7):470-472.
[5] 张志敏,季宝玉,李琳,等.恩替卡韦联合α-2b干扰素治疗慢性乙型肝炎的疗效观察[J].蚌埠医学院学报,2014,39(5):621-623.
[6] 刘洪波,单洪,秦丽莉,等.恩替卡韦联合聚乙二醇干扰素治疗慢性乙肝HBV-DNA 阴转患者疗效观察[J].山东医药,2015,55(2):105.
[7] 刘浩,徐琴,闫桂霞,等.长效干扰素联合恩替卡韦治疗慢性乙型病毒性肝炎的疗效观察[J].中国临床研究,2016,29(12):1644-1647.
[8] 陈雅萍,张勤俭,田楠楠,等.恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎患者疗效观察[J].实用肝脏病杂志,2016,19(2):208-209.
[9] 郑仕君,肖飞霞,张吉宏,等.慢性乙型肝炎患者应用恩替卡韦和干扰素α-2b治疗的临床效果观察[J].中华医院感染学杂志,2016,26(17):3895-3897.
[10] 惠威,李卓,郭新会,等.聚乙二醇干扰素联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者的疗效观察[J].中华全科医师杂志,2016,15(5):361-365.